NCT02104583
Completed
Phase 2
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)
ConditionsVentricular Arrhythmia
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Gilead Sciences
- Enrollment
- 313
- Locations
- 84
- Primary Endpoint
- Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24
Overview
Brief Summary
The primary objective of this study is to evaluate the effect of eleclazine (GS-6615) compared to placebo on the overall occurrence of appropriate implantable cardioverter-defibrillator (ICD) interventions (antitachycardia pacing [ATP] or shock) in adults with ICD or cardiac resynchronization therapy-defibrillator (CRT-D).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Have an ICD or CRT-D implanted for primary or secondary prevention and at least one ICD intervention for ventricular tachycardia/ventricular fibrillation (VT/VF) \[shock or ATP\] within 60 days prior to screening or a documented VT/VF episode (prior to implantation) within 60 days prior to screening
- •Use of highly effective contraception methods if female of childbearing potential or sexually active male
- •Must be hemodynamically stable
Exclusion Criteria
- •New York Heart Association (NYHA) Class IV heart failure
- •Myocardial infarction, unstable angina, coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI) within 4 weeks prior to screening or during the screening period before randomization
- •Hemodynamically significant primary obstructive valvular disease
- •History of congenital heart disease
- •Inherited arrhythmia such as Brugada syndrome. Individuals with long QT syndrome Type 3 (LQT-3) or hypertrophic cardiomyopathy (HCM) may be considered.
- •Individuals who are being considered for cardiac transplantation and are on a cardiac transplant list
- •History of seizures or epilepsy
- •Cardiac ablation within 3 months prior to screening or planned cardiac ablation during the study
- •Severe renal impairment
- •Abnormal liver function tests
Arms & Interventions
Eleclazine 3 mg
Experimental
Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 3 mg daily as maintenance for up to approximately 20 months.
Intervention: Eleclazine (Drug)
Eleclazine 6 mg
Experimental
Participants will receive a single loading dose of eleclazine 30 mg on Day 1, followed by eleclazine 6 mg daily as maintenance for up to approximately 20 months.
Intervention: Eleclazine (Drug)
Placebo
Placebo Comparator
Participants will receive a single loading dose of placebo to match eleclazine on Day 1, followed by placebo to match eleclazine once daily for up to approximately 20 months.
Intervention: Placebo to match eleclazine (Drug)
Outcomes
Primary Outcomes
Overall Occurrence (Total Number) of Appropriate Implantable Cardioverter-Defibrillator Device (ICD) Interventions (Anti-Tachycardia Pacing or Shock) Through Week 24
Time Frame: Randomization up to 24 weeks
Secondary Outcomes
- Overall Occurrence (Total Number) of Appropriate ICD Interventions (ATP or Shock) Through End of Study(Randomization up to 22 months)
- Change From Baseline in Premature Ventricular Complex (PVC) Count as Assessed by Continuous Electrocardiogram (cECG) Monitoring(Baseline to Week 12)
- Time From First Dose of Study Drug to the First Occurrence of CV Hospitalization, Emergency Room (ER) Visit, or CV Death(From first dose of study drug up to 22 months)
- Change From Baseline in Nonsustained Ventricular Tachycardia (nsVT) Count as Assessed by Continuous cECG Monitoring(Baseline to Week 12)
- Overall Occurrence (Total Number) of Ventricular Tachycardia/Ventricular Fibrillation (VT/VF) (Treated or Untreated) Through Week 24 and End of Study(Randomization up to Week 24; Randomization up to end of study (up to 22 months))
- Overall Occurrence (Total Number) of Electrical Storm Through Week 24 and End of Study(Randomization up to Week 24; Randomization up to end of study (up to 22 months))
- Overall Occurrence (Total Number) of Inappropriate ICD Interventions Through Week 24 and End of Study(Randomization up to Week 24; Randomization up to end of study (up to 22 months))
- Change in Left Ventricular Systolic and Diastolic Function as Assessed by Left Ventricular Ejection Fraction (LVEF)(Baseline to Week 12; Baseline to Week 24)
- Time From First Dose of Study Drug to the First Occurrence of Appropriate ICD Interventions (ATP or Shock) or Cardiovascular (CV) Death(From first dose of study drug up to 22 months)
Investigators
Study Sites (84)
Loading locations...
Similar Trials
Completed
Phase 1
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 SyndromeLQT2 SyndromeNCT02365506Gilead Sciences13
Terminated
Phase 2
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic CardiomyopathyHypertrophic CardiomyopathyNCT02291237Gilead Sciences172
Active, not recruiting
Phase 2
The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and CachexiaLung CancerNCT05919147Pennington Biomedical Research Center24
Terminated
Phase 3
Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic PainPainful Diabetic NeuropathyNCT01129960Bial - Portela C S.A.332
Terminated
Phase 3
Eslicarbazepine Acetate as Therapy in Post-Herpetic NeuralgiaPost Herpetic NeuralgiaNCT01124097Bial - Portela C S.A.240